|
EP2979693A1
|
|
Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
|
|
EP2610251A1
|
|
Novel polymorphic forms of dabigatran etexilate and process for the preparation thereof
|
|
EP2654723A1
|
|
Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
|
|
WO2012095151A1
|
|
Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
|
|
EP2604592A1
|
|
A process for the purification of aniracetam by crystallisation from aqueous solutions
|
|
EP2561864A1
|
|
Coated tablet comprising tianeptine and process for preparation thereof
|
|
EP2582362A1
|
|
Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
|
|
PL390015A1
|
|
Stereoselective method for synthesis of (S) - pregabalin
|
|
WO2010082855A1
|
|
Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
|
|
WO2009123483A1
|
|
Process for preparation of telmisartan
|
|
PL386416A1
|
|
Method of obtaining of [1-hydroxy-2-(1H-imidazole-1-yl)-ethylidene] bisphosphonic acid
|
|
PL386099A1
|
|
Method of obtaining the multicompartment lipid implant
|
|
PL371958A1
|
|
Method for the manufacture of [1-hydroxy-2-(3-pyridyl) ethylidene bis-phosphonic] acid and its 2 and a half aqueous monosodium salt
|
|
PL355354A1
|
|
Expression cassette, bi-cistron plasmide vector, pharmaceutical composition and their application
|
|
PL313359A1
|
|
Method of obtaining 1-{4-[2-(2-methoxy-5-chlorobenzamido)-ethyl]-benzosulphonyl}-3-cyclohexylurea
|
|
PL312857A1
|
|
Method of obtaining pharmaceutic form of prolonged-release verapamil chlorhydride
|
